BioSpace News Archive

Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate -based therapies, announced that it has relocated its UK headquarters to The Schrodinger Building within The Oxford Science Park.

Shanghai Kehua Bio-engineering Co., Ltd, China’s leading In Vitro Diagnostic company has achieved a significant milestone by becoming the first Chinese company to obtain EU Class D In Vitro Diagnostic Regulation certification for rapid tests.

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that underscores its commitment to advancing the wellbeing of psoriasis patients and their families through treatments and cutting-edge research.

AM-Pharma B.V. announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacement therapy in adult hypophosphatasia patients.

Kintor Pharmaceutical Limited announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional approval to conduct Phase II clinical trial in China by the National Medical Products Administration for treatment of idiopathic pulmonary fibrosis.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced collaboration with 3M Health Care.

BioCardia®, Inc. announces completion of enrollment in its CardiAMP Heart Failure Trial and initiation of a discussion with the FDA on a second pivotal study protocol adapted for the responders in the initial trial with the objective of gaining FDA marketing approval.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.

Kodiak Sciences Inc. announced that three scientific presentations on tarcocimab tedromer, including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration.

Pathnostics, a leading diagnostic solutions company, announced the publication of clinical study results showing that its advanced urinary tract infection test profoundly impacts patient care.